Sartorius Stedim Biotech 미래 성장

Future 기준 확인 4/6

Sartorius Stedim Biotech (는) 각각 연간 31.9% 및 10.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 31.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.7% 로 예상됩니다.

주요 정보

31.9%

수익 성장률

31.9%

EPS 성장률

Life Sciences 수익 성장	19.1%
매출 성장률	10.4%
향후 자기자본 수익률	13.7%
애널리스트 커버리지	Good
마지막 업데이트	18 Nov 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

BATS-CHIXE:DIMP - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	3,357	447	410	840	12
12/31/2025	3,003	340	333	748	12
12/31/2024	2,766	212	303	672	13
9/30/2024	2,736	161	504	866	N/A
6/30/2024	2,747	170	305	706	N/A
3/31/2024	2,716	255	169	636	N/A
12/31/2023	2,776	310	273	746	N/A
9/30/2023	2,959	460	113	625	N/A
6/30/2023	3,170	635	162	675	N/A
3/31/2023	3,356	717	137	606	N/A
12/31/2022	3,493	876	182	612	N/A
9/30/2022	3,381	681	125	552	N/A
6/30/2022	3,259	625	193	584	N/A
3/31/2022	3,094	559	322	661	N/A
12/31/2021	2,887	414	378	702	N/A
9/30/2021	2,639	523	355	623	N/A
6/30/2021	2,393	469	367	590	N/A
3/31/2021	2,143	398	310	506	N/A
12/31/2020	1,910	336	258	417	N/A
9/30/2020	1,743	299	299	414	N/A
6/30/2020	1,600	255	243	365	N/A
3/31/2020	1,520	254	216	345	N/A
12/31/2019	1,441	235	174	310	N/A
9/30/2019	1,393	247	142	291	N/A
6/30/2019	1,336	238	21	261	N/A
3/31/2019	1,274	223	88	270	N/A
12/31/2018	1,212	208	51	227	N/A
9/30/2018	1,172	185	57	226	N/A
6/30/2018	1,121	173	N/A	225	N/A
3/31/2018	1,093	162	N/A	196	N/A
12/31/2017	1,081	161	N/A	175	N/A
9/30/2017	1,073	151	N/A	165	N/A
6/30/2017	1,089	157	N/A	169	N/A
3/31/2017	1,075	157	N/A	146	N/A
12/31/2016	1,052	154	N/A	157	N/A
9/30/2016	1,009	145	N/A	146	N/A
6/30/2016	971	142	N/A	129	N/A
3/31/2016	926	136	N/A	155	N/A
12/31/2015	884	118	N/A	143	N/A
9/30/2015	850	111	N/A	150	N/A
6/30/2015	781	89	N/A	128	N/A
3/31/2015	734	76	N/A	113	N/A
12/31/2014	684	72	N/A	111	N/A
9/30/2014	646	71	N/A	93	N/A
6/30/2014	620	67	N/A	110	N/A
3/31/2014	604	68	N/A	97	N/A
12/31/2013	588	66	N/A	90	N/A

애널리스트 미래 성장 예측

수입 대 저축률: DIMP 의 연간 예상 수익 증가율( 31.9% )이 saving rate( 2.1% 보다 높습니다. ).

수익 vs 시장: DIMP 의 연간 수익( 31.9% ) UK 시장( 14.7% 보다 빠르게 성장할 것으로 예상됩니다. 14.7% 연간).

고성장 수익: DIMP 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: DIMP 의 수익(연간 10.4% ) UK 시장( 3.5% 보다 빠르게 성장할 것으로 예상됩니다. 3.5% 연간).

고성장 수익: DIMP 의 수익(연간 10.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: DIMP 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 13.7 %).

Sartorius Stedim Biotech 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

Recent updates

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025

Insufficient new directors

Investor sentiment deteriorates as stock falls 27%

Insufficient new directors

Upcoming dividend of €0.69 per share

New minor risk - Profit margin trend

Dividend of €0.69 announced

Insufficient new directors

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion.

Insufficient new directors

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Investor sentiment improves as stock rises 16%

Insufficient new directors

Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 15%

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Less than half of directors are independent

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Upcoming dividend of €1.26 per share

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020)

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020)

Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021

Sartorius Stedim Biotech Increases Earnings Guidance for 2021

Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019)

Revenue misses expectations

New 90-day high: €362

Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o.

Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million.

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견